|
OK Steve and others: I just talked to someone in AGPH research dep't and AG3340 (MMPI) IS an angiogenesis inhibitor drug and it's beyond just testing in mice (re: ENMD "drug," which, I think the CEO said, or implied, today on CNBC would not get into clinical trials for 3+ yrs, if ever; someone correct me if I'm wrong). AGPH is way beyond that stage and AG3340 is already in clinical trials. Sorry, I could not find out anything further about the progress of the AG3340 trials. AGPH is just a great company and is very far ahead of the pack. Yet, ENMD is up 39+ today (I would have liked to make that kind of profit in one day). FWIW, I'm sticking with AGPH, an established money-making company with a blockbuster drug on the market and a terrific pipeline in progress, including an angiogenesis inhibiting drug. PS: Everyone don't jump on me for providing this info (and don't plaster it all over the internet) as I am just stating what I understood the conversation to be (verify for yourself). It has just been my impression that AGP3340 is an angiogenesis inhibiting drug, and apparently I am correct. So, why doesn't AGPH go up 39+ in one day? This company doesn't brag about how well it's doing, IMO. It's just a good, honest company that is making honest money. |
